Navigation Links
Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
Date:12/8/2011

HORSHAM, Pa., Dec. 8, 2011 /PRNewswire-FirstCall/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765.  A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.  Interim data were reported at the 2011 American Society of Clinical Oncology Annual Meeting and oral presentations on two separate Phase 2 studies will be presented at the upcoming American Society of Hematology Meeting in December, along with several other poster presentations.

"The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies," said William N. Hait, M.D., Ph.D., Global Therapeutic Head, Oncology, for Janssen.  "PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies."

According to the terms of the agreement, the companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities.  Janssen has made an upfront payment of $150 million which will be recorded in the fourth quarter, and will make additional payments based upon the achievement of certain development and regulatory milestones.  This transaction is expected to have a dilutive impact to Johnson & Johnson's 2011 earnings per share of approximately $0.04 - $0.05.

About PCI-32765

PCI-32765 is an orally active, small molecule inhibitor of Bruton's tyrosine k
'/>"/>

SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research
2. FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
3. Skyline Diagnostics Establishes Research Collaboration With Janssen
4. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
5. Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research
6. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
7. Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
8. C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc
9. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
10. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
11. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... York, NY (PRWEB) November 14, 2014 ... plan, QuickSTAT is making significant investments in its ... world of modern cold chain and the complex ... support QuickSTAT’s ongoing focus on customized logistics and ... and enhancement of existing facilities. There will be ...
(Date:11/15/2014)... The "Operating Room Management Market by Product (Data ... operating room Scheduling), by Component (Software, Services), by ... 2019.” defines and segments the operating room management ... by product, such as data management, anesthesia, surgical ... volumes of operating room management market by applications ...
(Date:11/15/2014)... , November 14, 2014 ... has announced the addition of the  "Protein ... & Services, Application, & by End Users ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... valued at $1,569.00 million in 2014, and ...
(Date:11/12/2014)... 2014  ReachBio Research Labs (a registered trade name ... announced today that it has signed an agreement with ... giving Funakoshi non-exclusive distribution rights to ReachBio,s human primary ... within Japan . Under a companion ... services to Japanese drug development companies. Photo ...
Breaking Biology Technology:QuickSTAT Announces Global Expansion Plan to Enhance Its Global Network and Cold Chain Logistics Capabilities for Life Sciences 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 2Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 3Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 2Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 3
... 11, Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA ... ), announced today that,they have entered into a ... Possis Medical in a cash tender offer for ... of approximately US-Dollar 361,million. The offer price represents ...
... a Living ... Cell-Based Therapy, ... to successfully mass-produce living regenerative medicine products,is again breaking new ... living cell-based therapy. As the first,bio-engineered living cell therapy to ...
... Corporation ("AGA"),announced today it received European CE Mark approval ... announced the immediate availability,and launch of the device in ... devices designed to occlude or close a patent ductus ... when a blood vessel,called the ductus arteriosus fails to ...
Cached Biology Technology:Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 2Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 3Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 4AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II 2
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
(Date:11/4/2014)... A majority of Madagascar,s 101 species of lemurs are ... for the rainforests they call home. A new study ... can have on rainforest tree populations, which raises concerns ... the region,s rich biodiversity. , A large proportion of ... Lemurs in turn disperse the seeds of their ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... PHILADELPHIA - Mo Salman, professor of animal population health ... 2010 recipient of the Penn Vet World Leadership Award, ... Veterinary Medicine to a veterinarian who has dramatically ... lives of others. The $100,000 in unrestricted funding, ...
... Scientists are reporting the development and successful initial testing of ... designed to be given as nose drops rather than ... brain cancer, they say. The report appears in ACS, ... and colleagues note that brain cancer is difficult to treat, ...
... Imagine devices that capture electricity from the air much ... light a house or recharge an electric car. Imagine using ... before it forms. Strange as it may sound, scientists already ... to a report at the 240th National Meeting of the ...
Cached Biology News:Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards 2Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards 3Electricity collected from the air could become the newest alternative energy source 2
... Science, which pioneered the blending of thermostable ... and Expand Long Template PCR Systems, now ... the first product of a family ... blend combines Taq DNA Polymerase with a ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
...
... Plus DNA Polymerase with a proprietary thermostable ... fidelity than standard Taq DNA polymerase, Double ... Amplifies DNA templates >20kb, Concentration: 5U/ul, Applications: ... cloning and mutagenesis We are part of ...
Biology Products: